SUBSCRIBE

Breaking News on Food, Beverage & Supplement Development - Asia PacificEU edition | US edition

Headlines > Nutrition

News in brief

Australian institute to study ChromaDex's Niagen ingredient in mitochondrial respiratory conditions

Post a commentBy Hank Schultz , 04-Aug-2014
Last updated on 05-Aug-2014 at 16:38 GMT

Niagen supports mitochondrial health, ChromaDex says.
Niagen supports mitochondrial health, ChromaDex says.

ChromaDex Corp. announced an agreement to supply its Niagen nicotinamide riboside ingredient to the Murdoch Children’s Research Institute in Australia to enable researchers there to study the ingredient’s effects in cellular and animal models of mitochondrial respiratory diseases.

Niagen is the only commercially available form of nicotinamide riboside (NR), which is a naturally occurring vitamin B3 derivative found in milk. Published research has shown that NR is perhaps the most effective precursor to boost the co-enzyme NAD+ in the cell.  NAD+ is an important cellular co-factor for improvement of mitochondrial performance and energy.  NAD+ is essential in supporting healthy cellular metabolism including the efficient conversation of blood glucose into energy. 

Dr. David Thorburn, Mitochondrial Research group head at Murdoch Childrens Research Institute, together with Dr. Ann Frazier and Dr. Bi-Xia Ke, and supported by a grant from the Australian Mitochondrial Disease Foundation, will study the response to NR in mouse models with mitochondrial Complex I deficiency and in a range of human and mouse cell lines with impaired mitochondrial function.

In addition to Niagen, ChromaDex also supplies pTeroPure pterostilbene; ProC3G, a natural black rice containing cyanidin-3-glucoside; and Purenergy, a caffeine-pTeroPure co-crystal.  The company also performs analytical testing services and coslting services via its Spherix Consulting subsidiary.

Subscribe to our FREE newsletter

Get FREE access to authoritative breaking news, videos, podcasts, webinars and white papers. SUBSCRIBE

Post a comment

Comment title *
Your comment *
Your name *
Your email *

We will not publish your email on the site

I agree to Terms and Conditions

These comments have not been moderated. You are encouraged to participate with comments that are relevant to our news stories. You should not post comments that are abusive, threatening, defamatory, misleading or invasive of privacy. For the full terms and conditions for commenting see clause 7 of our Terms and Conditions ‘Participating in Online Communities’. These terms may be updated from time to time, so please read them before posting a comment. Any comment that violates these terms may be removed in its entirety as we do not edit comments. If you wish to complain about a comment please use the "REPORT ABUSE" button or contact the editors.

Related products

Key Industry Events

 

Access all events listing

Our events, Events from partners...